POSA107 Apixaban Versus Other Anticoagulants in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: A Comparison of All-Cause and Event-Related Costs in Real-Life Setting in France

M Belhassen,O Hanon,Pg Steg,I Mahé,M Née,F Jacoud,F Dalon,Fe Cotte,S Gollety,C Marant-Micallef,E Van Ganse,B Falissard,N Danchin

doi:10.1016/j.jval.2021.11.251

Abstract

To estimate and compare costs associated with all-cause healthcare resource use (HCRU), stroke/systemic embolism (SE) and major bleedings (MB) between patients with non-valvular atrial fibrillation (NVAF) initiating apixaban and patients initiating other oral anticoagulants (OAC).

Full Text